Lataa...
Advances in the development of new biologics in inflammatory bowel disease
Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently be...
Tallennettuna:
| Julkaisussa: | Ann Gastroenterol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Hellenic Society of Gastroenterology
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4923809/ https://ncbi.nlm.nih.gov/pubmed/27366024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2016.0027 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|